文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

α与β⁻发射体靶向放射核素治疗的放射生物学效应差异:DNA损伤与存活

Differential Radiobiological Effects of Alpha- and Beta-Minus-Emitter Targeted Radionuclide Therapy: DNA Damage and Survival.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2026-08-26

本研究以前列腺癌细胞系为对象,比较225Ac(α发射体)与177Lu(β⁻发射体)标记PSMA放射性药物及非靶向核素的放射生物学效应。结果显示α发射体在仅1%活度下即诱导相当DNA双链断裂,且损伤持续达72小时;联合DNA-PK抑制剂Nedisertib可显著增强疗效并大幅降低所需活度。

要点

  • α发射体在1%活度下即可诱导与β⁻发射体相当的DNA双链断裂。
  • PSMA介导内化对短程α-TRT增强显著,对长程β⁻-TRT影响可忽略。
  • 联合Nedisertib使225Ac所需活度降低64倍、177Lu降低4倍。

核心结论

  • 细胞内化对短程α发射体至关重要,β⁻发射体则依赖高结合亲和力与滞留。
  • 不同核素DNA修复动力学差异体现放射生物学效应特异性。
  • TRT联合DNA-PK抑制是有望增强疗效、降低活度并可能减轻毒性的策略。

研究设计与样本

  • 研究为体外细胞实验,使用PSMA阳性LNCaP和C4-2及PSMA阴性PC-3前列腺癌细胞系。
  • 细胞暴露于225Ac或177Lu标记PSMA放射性药物或非靶向核素1或4小时,α发射体活度1-100 kBq,β⁻发射体100-5000 kBq。
  • 以外照射放疗0.5-2.5 Gy为参照,用免疫荧光γH2AX量化DNA双链断裂并辅以细胞活力检测。
  • 开展与DNA-PK抑制剂Nedisertib(M3814)的概念验证联合研究。

主要发现

  • α发射体优于β⁻发射体,在仅1%应用活度下即诱导 comparable DNA双链断裂。
  • PSMA介导内化强烈增强短程α-TRT,对长程β⁻-TRT影响可忽略。
  • α诱导的DNA双链断裂持续长达72小时,而β⁻-TRT和外照射后DNA双链断裂随时间减少。
  • 联合Nedisertib显著增强C4-2细胞中TRT疗效,使所需活度分别降低64倍(225Ac)和4倍(177Lu)。
  • 在放射敏感性最低的PC-3细胞中,联合α-TRT与Nedisertib后细胞活力降至50%以下。

临床怎么用

  • 设计放射性药物时,短程α发射体应优先考虑实现细胞内化。
  • 使用β⁻发射体时需关注高结合亲和力与滞留以保障疗效。
  • TRT联合DNA-PK抑制可能增强疗效并支持活度降阶梯。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Metastatic cancer remains a major challenge, demanding more effective and biologically informed therapeutic strategies. Targeted radionuclide therapy (TRT) holds significant promise, but limited understanding of treatment response and resistance hinders its optimization. This work aimed to improve TRT efficacy and overcome radioresistance by determining how radionuclide properties, administered activity, and subcellular localization govern radiobiological outcomes. The objectives were to advance TRT for prostate cancer, overcome radioresistance, and generate mechanistic insights to guide radiopharmaceutical design and radionuclide selection. METHODS AND MATERIALS: Prostate-specific membrane antigen (PSMA)-positive (LNCaP [lymph node adenocarcinoma of the prostate] and C4-2) and PSMA-negative (PC-3) prostate cancer cell lines were exposed to 225Ac- or 177Lu-labeled PSMA radiopharmaceuticals or nontargeted radionuclides for 1 or 4 hours across activity ranges for α-emitters (1-100 kBq) and β⁻-emitters (100-5000 kBq), with external beam radiation therapy (0.5-2.5 Gy) as a reference. DNA double‑strand breaks (DSBs) were quantified by immunofluorescence‑based γH2AX analysis and complemented by cell viability assays. A proof‑of‑concept combination study with the DNA-dependent protein kinase (DNA-PK) inhibitor Nedisertib (M3814; Selleck Chemicals, Houston, TX, USA) was performed. RESULTS: The α-emitters outperformed the β⁻-emitters, inducing comparable DSBs at only 1% of the applied activity. PSMA‑mediated internalization strongly enhanced short‑range α‑TRT but had negligible impact on longer‑range β⁻‑TRT. α‑Induced DSBs persisted for up to 72 hours, whereas DSBs decreased over time after β⁻‑TRT and external beam radiation therapy. Combination therapy with Nedisertib significantly enhanced TRT efficacy in C4-2 cells, enabling a 64‑fold (225Ac) versus 4‑fold (177Lu) reduction in required activity. In the least radiosensitive PC-3 cells, viability decreased to below 50% following combined α-TRT and Nedisertib treatment. CONCLUSIONS: Our study defines key determinants for optimizing TRT. Cellular internalization is critical for short-range α-emitters, whereas β⁻-emitters depend on high binding affinity and retention, providing experimental guidance for radiopharmaceutical design and radionuclide selection. Distinct DNA repair kinetics underscore radionuclide‑specific biological effects. Combining TRT with DNA‑PK inhibition is a promising strategy to enhance efficacy, enable activity de‑escalation, and potentially mitigate toxicity.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Winter RC, Bauder-Wüst U, Schäfer M, et al. Differential Radiobiological Effects of Alpha- and Beta-Minus-Emitter Targeted Radionuclide Therapy: DNA Damage and Survival. Int J Radiat Oncol Biol Phys. 2026. PMID: 42648579. doi:10.1016/j.ijrobp.2026.08.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。